Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK-Reference-Cited by-同舟云学术

Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK

Published:2022-05-27 Issue:1 Volume:25 Page:669-678
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Montgomery S.¹^ORCID,Woodhouse F.¹^ORCID,Vudumula U.²^ORCID,Gudala K.³,Duddy M.⁴^ORCID,Kroes M.⁵

Affiliation:

1. Costello Medical Consulting Ltd, Cambridge, UK

2. Novartis Ireland Limited, Dublin, Ireland

3. Novartis Healthcare Private Limited, Hyderabad, India

4. Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK

5. Novartis Pharmaceuticals UK Ltd, London, UK

Funder

Novartis Pharmaceuticals UK Ltd

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2078103

Reference40 articles.

1. Multiple sclerosis

2. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis

3. Multiple Sclerosis Trust – Prevalence and Incidence of Multiple Sclerosis [cited 2021 June 08]. Available from: https://mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis.

4. MS Society. Types of MS. [cited 2021 June 03]. Available from: https://www.mssociety.org.uk/about-ms/types-of-ms/relapsing-remitting-ms.

5. Natural history of secondary-progressive multiple sclerosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series;Clinical Neurology and Neurosurgery;2024-10

2. The interplay between mitochondrial dysfunction and NLRP3 inflammasome in multiple sclerosis: Therapeutic implications and animal model studies;Biomedicine & Pharmacotherapy;2024-06

3. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16

4. Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study;ClinicoEconomics and Outcomes Research;2024-02

5. The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis;Drugs in R&D;2023-08-28